Rallybio has dosed the first subject in a trial of a potential treament for foetal and neonatal alloimmune thrombocytopaenia (FNAIT).

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

Regeneron has reported positive outcomes from the Phase III trial of Eylea HD in treating individuals with macular oedema ...

In addition to Hitler, the entire Nazi leadership, the scientists who designed so many weapons, even in a very short range of ...

MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

Quantum BioPharma Ltd (NASDAQ:QNTM) shares are rising Tuesday after the company announced positive clinical trial results for ...

In a survey, less than half of cancer patients and their family members said they were willing to participate in a clinical trial, and about a third of respondents said they had a positive perception ...

Two top clinicians have been disciplined amid growing concern that Kaiser’s system for monitoring research safety and ethics ...

Adverse Events (AE) and AR reports on marketed drugs occurring as part of confirmatory trials subject to clinical trial applications, as outlined in the Letter of Undertaking, must be reported as per ...

Neuren said it also planned to advance Pitt Hopkins syndrome and Angelman syndrome to phase III trials, subject to FDA consultation, following positive phase II trial results. The company’s first drug ...